drugset / Trial / NCT05372783
Study to Evaluate the Efficacy of IN STI-9199 in Treating Symptomatic COVID-19 in Outpatient Adults and Adolescents
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a Phase 2 global, randomized, double-blind, placebo-controlled study designed to investigate the safety and preliminary efficacy of intranasal STI-9199 in adults and adolescents who are COVID-19 positive with mild to moderate symptoms.
Timeline
- Start
- 2023-04
- Primary completion
- 2024-06
- Completion
- 2024-10
Outcome
Outcome not reported
Stopped: “Study was never launched”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | STI-9199 | Monoclonal antibody | 4 mg | Intranasal |
| Subject | STI-9199 | Monoclonal antibody | 10 mg | Intranasal |
| Subject | STI-9199 | Monoclonal antibody | 20 mg | Intranasal |